skip to main content

This content will become publicly available on November 1, 2016

Title: Transcriptional control of Sost in bone [Transcriptional control of Sclerostin]

Sclerostin is an osteocyte derived negative regulator of bone formation. A highly specific expression pattern and the exclusive bone phenotype have made Sclerostin an attractive target for therapeutic intervention in treating metabolic bone diseases such as osteoporosis and in facilitating fracture repair. Understanding the molecular mechanisms that regulate Sclerostin transcription is of great interest as it may unveil new avenues for therapeutic approaches. Such studies may also elucidate how various signaling pathways intersect to modulate bone metabolism. Furthermore we review the current understanding of the upstream molecular mechanisms that regulate Sost/SOST transcription, in bone.
Authors:
 [1] ;  [1]
  1. Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States); Univ. of California, Merced, CA (United States)
Publication Date:
OSTI Identifier:
1330597
Report Number(s):
LLNL-JRNL-691682
Journal ID: ISSN 8756-3282
Grant/Contract Number:
AC52-07NA27344; 16-ERD-007
Type:
Published Article
Journal Name:
Bone
Additional Journal Information:
Journal Volume: 96; Journal Issue: C; Journal ID: ISSN 8756-3282
Publisher:
Elsevier
Research Org:
Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
Sponsoring Org:
USDOE
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES